PharmaShots | Incisive News in 3 Shots

Subscribe Now

leo pharma

LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)

LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)

July 26, 2024

LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (AD)

LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (...

June 13, 2024

Leo Pharma to Acquire Timber for ~$36M

Leo Pharma to Acquire Timber for ~$36M

August 22, 2023

PharmaShots Weekly Snapshots (February 06 - 10, 2023)

PharmaShots Weekly Snapshots (February 06 - 10, 2023)

February 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema

February 10, 2023

LEO Pharma’s Adtralza (tralokinumab) Receives the Health Canada’s Approval for the Treatment of Atopic Dermatitis

LEO Pharma’s Adtralza (tralokinumab) Receives the Health Canada’s Approval for the Treatment of Atopic Dermatitis

February 9, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us